Hypha Labs net loss narrows 45.77% to $304,757 in Q3 FY26; operating loss shrinks 82.1% to $95,953

• Hypha Labs posted a net loss of $304,757 in the quarter ended June 30, 2026, narrowing 45.77%.
• Operating loss narrowed to $95,953 as total operating expenses fell 82.1% to $95,953.
• Professional fees dropped 93% to $29,534, reflecting lower stock-based compensation, consulting services, and legal fees.
• Other expense widened to $208,804, driven by higher interest expense; results also included a $54,295 derivative-liability fair-value loss.
• Hypha aims to market its Hypha Micropearl bioreactor in the latter part of calendar 2026, pending design completion and testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hypha Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038297), on August 14, 2026, and is solely responsible for the information contained therein.